Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Other Non-Current Liabilities (2017 - 2023)

Denali Therapeutics (DNLI) has disclosed Other Non-Current Liabilities for 7 consecutive years, with $379000.0 as the latest value for Q3 2023.

  • On a quarterly basis, Other Non-Current Liabilities changed 0.0% to $379000.0 in Q3 2023 year-over-year; TTM through Sep 2023 was $379000.0, a 0.0% change, with the full-year FY2022 number at $379000.0, changed 0.0% from a year prior.
  • Other Non-Current Liabilities was $379000.0 for Q3 2023 at Denali Therapeutics, roughly flat from $379000.0 in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $701000.0 in Q4 2020 to a low of $379000.0 in Q4 2019.
  • A 5-year average of $441529.4 and a median of $379000.0 in 2019 define the central range for Other Non-Current Liabilities.
  • Peak YoY movement for Other Non-Current Liabilities: surged 134.04% in 2019, then plummeted 45.93% in 2021.
  • Denali Therapeutics' Other Non-Current Liabilities stood at $379000.0 in 2019, then surged by 84.96% to $701000.0 in 2020, then tumbled by 45.93% to $379000.0 in 2021, then changed by 0.0% to $379000.0 in 2022, then changed by 0.0% to $379000.0 in 2023.
  • Per Business Quant, the three most recent readings for DNLI's Other Non-Current Liabilities are $379000.0 (Q3 2023), $379000.0 (Q2 2023), and $379000.0 (Q1 2023).